<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000644756">
  <TermName>muramyl tripeptide phosphatidylethanolamine</TermName>
  <TermPronunciation>(MYOOR-uh-mil try-PEP-tide FOS-fuh-TY-dul-EH-thuh-NOH-luh-meen)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A drug being studied in the treatment of young adults with bone cancer that has gotten worse or come back. Muramyl tripeptide phosphatidylethanolamine activates certain types of white blood cells and helps the immune system kill cancer cells. It is a type of immunostimulant. Also called L-MTP-PE, MEPACT, and mifamurtide.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000726270" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;muramyl tripeptide phosphatidylethanolamine&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000726271" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;muramil tripéptido fosfatidiletanolamina&quot;" language="es" id="_4"/>
  <SpanishTermName>muramil tripéptido fosfatidiletanolamina</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento en estudio para el tratamiento de adultos jóvenes con cáncer de hueso que ha empeorado o ha reaparecido. El muramil tripéptido fosfatidiletanolamina activa ciertos tipos de células sanguíneas y ayuda al sistema inmunitario a eliminar las células cancerosas. Es un tipo de inmunoestimulante. También se llama L-MTP-PE, MEPACT y mifamurtida.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-11-09</DateFirstPublished>
</GlossaryTerm>
